Receipt of 25kg of GMP-Grade Monepantel from Elanco

- PharmAust shores up GMP monepantel supply for future clinical trials

8 May 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to announce it has received 25 kilograms of GMP-grade monepantel to support its clinical trial program. This has been received from Elanco US Inc based on the Option Agreement announced on 18 April 2018.

PharmAust's Chief Scientific Officer, Dr Richard Mollard stated, "PharmAust is thankful to Elanco for providing this second batch of GMP grade monepantel. Receipt of the initial batch last year was instrumental in establishing the GMP grade tableting program for the imminent Phase II clinical trial program in dogs with cancer. This new batch is expected to provide sufficient drug to extend PharmAust's clinical trial programs through the next two to three years."

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epichem, is a successful contract medicinal chemistry company that generated $3m revenues in FY2018.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug to Phase 2 clinical trials.

www.pharmaust.com